Wells Fargo Healthcare Conference, Thursday, September 7, 1:40 p.m. ETat Westin Boston Waterfront, Boston, Massachusetts Morgan Stanley15th Annual Global Healthcare Conference, Wednesday, September 13, 9:55 a.m. ETat the Grand Hyatt, New York City
LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology,
Thursday, September 28, 9:30 am ETat the Lotte New York Palace, New York City
To access the live webcast of bluebird bio’s presentation, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the conference.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’sproduct candidates and research programs. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks that the preliminary results from our clinical trials will not continue or be repeated in our ongoing clinical trials, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, the risk of a delay in the enrollment of patients in our clinical studies, risks that the current or planned clinical trials of the LentiGlobin drug product will be insufficient to support regulatory submissions or marketing approval in the
Source: bluebird bio, Inc.